I’ve spent 11 years in the trenches of pharma commercial ops and managed markets. I’ve sat through thousands of minutes of "strategic alignment" meetings that resulted in absolutely nothing. When you walk out of a session at THMA (The Health Management Academy) or an ACCC (Association of Cancer Care Centers) summit, you are likely exhausted. But if you’re a market access leader, the exhaustion is a luxury you can’t afford.
The biggest trap teams fall into after these conferences is the "great networking" fallacy. You swapped business cards, you heard a Health System CFO complain about reimbursement, and you took a picture of a slide. If you don't have a plan for Monday morning, that engagement is a sunk cost. Let’s stop pretending that shaking hands is the same as securing access.
Stop Confusing Prescriber Reach with Market Access
Too many teams conflate traditional sales reach with market access strategy. Sales teams want more reps in the field to talk to physicians. Market access teams need to be talking to the people who decide whether a drug even makes it onto the hospital’s formulary list. If you are still using your sales force to solve access problems, you have already failed.
When you talk to health system executives at events like those hosted by AMCP (Academy of Managed Care Pharmacy), you shouldn't be pitching the clinical profile. You should be stress-testing your formulary positioning plan against their current financial volatility. If the executive says their system is "re-evaluating high-cost biologics," your response shouldn't be "but the data is great." Your response should be "how does our value dossier align with your internal risk-sharing model?"
The Reality of "Who You Actually Meet"
I keep a running spreadsheet of every major stakeholder interaction. In the "Who You Actually Meet" column, I don't just put names. I put: “CFO, cost-conscious, hates long-term contracts” or “Chief Pharmacy Officer, looks for HTA-driven evidence over vanity metrics.”
When you sit in a room with these stakeholders, you are performing a live, high-stakes health system stakeholder mapping exercise. If you aren’t documenting the specific pain points they mention—not the vague "access is hard" but the specific https://stateofseo.com/how-to-actually-justify-market-access-conference-travel-to-your-vp/ "reimbursement codes for this drug are being denied 14% of the time in the Northeast region"—then you are wasting their time and yours.
How to Translate Insights into Access Execution Steps
After a conference, the "What would I do differently on Monday?" question is my north star. It forces me to move from passive listening to active deployment. Here is a breakdown of how to structure your post-conference analysis:
The Role of Digital Tools and Evidence
Modern access is not https://bizzmarkblog.com/are-executive-forums-better-than-big-conferences-for-real-access-decisions/ just about the narrative; it’s about the math. You need to leverage digital tools in evidence generation and reimbursement to show health systems exactly what their financial exposure looks like. Executives at THMA-style roundtables aren't interested in your marketing decks. They are interested in your cost-offset models.
Think about the digital environment they live in. Even when browsing your own company’s portal for technical specs, they encounter the same friction users everywhere do. If your team is struggling to navigate a site because of clunky Cookie Law Info plugin UI elements and pop-ups that block the data they actually need, you are losing them. Why? Because they equate that friction with your company’s internal operations. If you can’t get your web experience right, how can they trust you with their complex formulary execution?
Addressing Pricing and HTA Pressure
Health systems are under immense HTA (Health Technology Assessment) pressure. They have a finite pool of capital, and every dollar spent on your drug is a dollar taken from another department. If your post-conference strategy doesn't address affordability, it is incomplete.
When you are back in the office, use the insights from your stakeholder mapping to refine your value proposition. Don’t just talk about the clinical efficacy. Talk about the "Total Cost of Care." If you met an executive who emphasized "readmission rates," your formulary positioning plan must explicitly link your therapy to lower readmissions. If you can’t make that link, don’t expect a preferred status.
Refining Your Formulary Positioning Plan
Your formulary positioning plan should be a living document. After a congress, it should look like a war room map. Every time you speak to a health system executive, update the plan. Does this system require a specific type of evidence for clinical pathways? Does that system have a specific pharmacy benefits committee that meets on the third Tuesday of every month?
If you aren't tracking this level of detail, you are just throwing mud at the wall. Stop using buzzwords like "synergy." There is no synergy. There is only mutual interest and contractual obligation. Use those terms. Get blunt.
The Monday Morning Checklist
If you really want to change how your market access team operates after a major industry event, execute these three steps on Monday morning:
The Evidence Audit: Take one specific claim you heard from an executive and ask, "Do we have a digital evidence tool that demonstrates this metric to their finance team?" If no, start building it. The Stakeholder Update: Open your mapping spreadsheet. Tag every executive you met with one specific barrier to entry they mentioned. Don't write "needs more info." Write "requires budget impact analysis for the 2025 fiscal year." The Strategy Pivot: Identify one access execution step that your current team is ignoring because it’s "too difficult." That’s exactly where the competitive advantage lies. Do the hard thing first.Conclusion: Move Past the Fluff
The industry is filled with people who love the idea of "strategic networking." But when the lights go down and the conference halls empty, the only thing that matters is whether you secured the formulary slot. The health system executives you met at AMCP or ACCC don't care about your brand's mission statement. They care about their own internal margins and their patients' outcomes.
If you want to move the needle, stop asking how to "streamline" your message. Start asking how to provide better data to the people who control the budgets. Keep a better spreadsheet. Map your stakeholders more aggressively. And for heaven’s sake, stop wasting time with buzzwords. Your job is to facilitate access. Do that, and the results will take care of themselves.